Solis Pharms

Solis Pharmaceuticals is a specialty pharmaceutical company focused on the development, manufacturing, and commercialization of high-quality medicines across diverse therapeutic areas, including neurology, psychiatry, orthopedics, and women's health. Headquartered in Hyderabad, India, the company maintains a significant presence in the United States market through its subsidiary, Solis Pharmaceuticals Inc., which holds several Abbreviated New Drug Applications (ANDAs) for essential generic medications. Its product portfolio includes well-known treatments such as dapsone, fluoxetine, and piroxicam, as well as specialized formulations for pain and sleep management. In June 2023, Solis Pharmaceuticals was acquired by PI Health Sciences, a subsidiary of PI Industries, to bolster its pharmaceutical value chain and expand its reach in the global healthcare market. The company is recognized for its expertise in brand management and its commitment to providing affordable, trusted healthcare solutions.